SELLAS Life Sciences (SLS) EBITDA Margin (2012 - 2016)
SELLAS Life Sciences' EBITDA Margin was -266.11% in Q2 2015, up 401.15 percentage points from -667.27% a year earlier and up 54.39 percentage points from the prior quarter.
Powered by 
Analysis
SELLAS Life Sciences (SLS) EBITDA Margin (2012 - 2016) Analysis & Trends
On a trailing twelve-month basis, SELLAS Life Sciences' EBITDA Margin was -351.23% through Jun 30, 2015, up 86.78 percentage points year-over-year; for FY2014, it came in at -470.16%, up 663.86 percentage points from FY2013.
- In earlier years, EBITDA Margin was -1134.02% in FY2013.
- The Q2 2015 figure marks the highest quarterly EBITDA Margin since Q4 2013.
- Compared with a year earlier, EBITDA Margin was higher in three of the last seven quarters, with an average year-over-year change of -32.15 percentage points.
- Per Business Quant data, SLS's EBITDA Margin in the three quarters before Q2 2015 was -320.51% (Q1 2015), -311.33% (Q4 2014) and -659.75% (Q3 2014).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | SELLAS Life Sciences | 2.30 Bn | 1.94 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 1,052.55% |
| Jun 30, 2015 | -266.11% |
| Mar 31, 2015 | -320.51% |
| Dec 31, 2014 | -311.33% |
| Sep 30, 2014 | -659.75% |
| Jun 30, 2014 | -667.27% |
| Mar 31, 2014 | -534.61% |
| Dec 31, 2013 | -215.37% |
| Sep 30, 2013 | -417.65% |
| Jun 30, 2013 | -340.93% |
| Mar 31, 2013 | -304.14% |
| Sep 30, 2012 | -472.22% |
API Access
SELLAS Life Sciences EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SLS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "SLS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SLS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();